Atıf Formatları
Chemotherapy Choice in Neoadjuvant Dual Her2 Blockade: Is it Really Essential to Add Anthracycline?
  • IEEE
  • ACM
  • APA
  • Chicago
  • MLA
  • Harvard
  • BibTeX

A. ÖZVEREN Et Al. , "Chemotherapy Choice in Neoadjuvant Dual Her2 Blockade: Is it Really Essential to Add Anthracycline?," Eurasian Journal of Medical Investigation , vol.7, no.1, pp.63-68, 2023

ÖZVEREN, A. Et Al. 2023. Chemotherapy Choice in Neoadjuvant Dual Her2 Blockade: Is it Really Essential to Add Anthracycline?. Eurasian Journal of Medical Investigation , vol.7, no.1 , 63-68.

ÖZVEREN, A., ERDOĞAN, A. P., EKİNCİ, F., KIRDÖK, K., ALMURADOVA, E., & KARABULUT, B., (2023). Chemotherapy Choice in Neoadjuvant Dual Her2 Blockade: Is it Really Essential to Add Anthracycline?. Eurasian Journal of Medical Investigation , vol.7, no.1, 63-68.

ÖZVEREN, AHMET Et Al. "Chemotherapy Choice in Neoadjuvant Dual Her2 Blockade: Is it Really Essential to Add Anthracycline?," Eurasian Journal of Medical Investigation , vol.7, no.1, 63-68, 2023

ÖZVEREN, AHMET Et Al. "Chemotherapy Choice in Neoadjuvant Dual Her2 Blockade: Is it Really Essential to Add Anthracycline?." Eurasian Journal of Medical Investigation , vol.7, no.1, pp.63-68, 2023

ÖZVEREN, A. Et Al. (2023) . "Chemotherapy Choice in Neoadjuvant Dual Her2 Blockade: Is it Really Essential to Add Anthracycline?." Eurasian Journal of Medical Investigation , vol.7, no.1, pp.63-68.

@article{article, author={AHMET ÖZVEREN Et Al. }, title={Chemotherapy Choice in Neoadjuvant Dual Her2 Blockade: Is it Really Essential to Add Anthracycline?}, journal={Eurasian Journal of Medical Investigation}, year=2023, pages={63-68} }